Comparing Lifeward (NASDAQ:LFWD) and Femasys (NASDAQ:FEMY)

Lifeward (NASDAQ:LFWD) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Lifeward has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.07, meaning that its stock price is 307% less volatile than the S&P 500.

Institutional and Insider Ownership

26.8% of Lifeward shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 7.7% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Lifeward and Femasys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
Femasys	-534.36%	-225.97%	-74.68%

Valuation & Earnings

This table compares Lifeward and Femasys”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03 million	0.91	-$19.91 million	($16.82)	-0.42
Femasys	$2.29 million	10.82	-$18.63 million	($3.53)	-0.84

Femasys has lower revenue, but higher earnings than Lifeward. Femasys is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Lifeward and Femasys, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1	1	2	0	2.25
Femasys	1	0	3	0	2.50

Lifeward presently has a consensus target price of $10.00, indicating a potential upside of 41.34%. Femasys has a consensus target price of $50.00, indicating a potential upside of 1,591.47%. Given Femasys’ stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Lifeward.

Summary

Femasys beats Lifeward on 10 of the 14 factors compared between the two stocks.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.